# US 2016/0354366 A1 · Novel use of trimetazidine as a hepatoprotective medicine in prevention and treatment of liver diseases and conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354366 A1
- Document ID: US20160354366A1
- Status: Published application
- Kind: A1
- Application number: 15/240,677
- Filed: 2016-08-18
- Published: 2016-12-08
- Earliest claimed: 2015-04-28
- Assignees: Martin Pharmaceuticals, Inc.
- Inventors: Zujiang Yu
- Web page: https://patentgrep.com/patent/US20160354366A1

## CPC

- A61K 31/4965: Non-condensed pyrazines
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This present invention discloses a new use of trimetazidine as a hepatoprotective drug in prevention and treatment of liver diseases, wherein trimetazidine is capable of inhibiting activation of resting T lymphocytes to activated lymphocytes, reducing release of cytokines, and reducing the hepatocyte injury caused by the immune system; capable of inhibiting fatty acid metabolism in hepatocytes and optimizing energy process in hepatocytes; and capable of maintaining normal function of mitochondrial permeability transition pores and reducing hepatocyte apoptosis. Clinical research and trial results suggest that, when administered to patients suffering from liver diseases and conditions, trimetazidine is capable of providing significant hepatoprotective function, and effectively decreasing transaminase levels (including alanine aminotransferase, aspartate transaminase, etc.), with such features as shortening the course of disease, reducing the mortality rate, easy and safe use, and low treatment cost. Trimetazidine is eliminated unchanged mainly through urine, with the elimination half-life of approximately 6 hours, and without hepatic metabolism. Therefore, trimetazidine has minimal liver toxicity, while having significant hepatoprotective effect.

## Claims

### Claim 1

A method for treating a liver disease or condition, comprising administrating to a subject in need thereof a pharmaceutical composition comprising an effective amount of trimetazidine or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is orally administered to the subject.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is parentally administered to the subject.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is administered to the subject 1-4 times daily.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is administered to the subject 2 or 3 times daily.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the subject is administered with about 30-180 mg daily of trimetazidine or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the subject is administered with about 60 mg daily of trimetazidine or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein active ingredient of the pharmaceutically composition consists essentially of trimetazidine or a pharmaceutically acceptable salt thereof

### Claim 9 (depends on 1)

The method according to claim 1, wherein active ingredient of the pharmaceutically composition consists of trimetazidine or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the pharmaceutically composition further comprises a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the liver disease or condition is hepatitis or cirrhosis.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the liver disease or condition is viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, alcoholic fatty liver disease, or non-alcoholic fatty liver disease.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the liver disease or condition is liver failure.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the liver disease or condition in absence of treatment develops into acute liver failure in a month, a week, or 72 hours.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the subject is not suffering from angina pectoris, coronary insufficiency, old myocardial infarction, coronary heart disease, vertigo or tinnitus.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the pharmaceutically composition reduces activation of resting T lymphocytes to activated lymphocytes in the subject.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the pharmaceutically composition reduces fatty acid metabolism in hepatocytes and promotes aerobic oxidation of glucose in the subject.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the pharmaceutically composition reduces β-oxidation in hepatocytes and reduces formation of ROS in the subject.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the pharmaceutically composition reduces blood alanine aminotransferase (ALT) level in the subject by at least 100 U/L after 15 days of treatment.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the pharmaceutically composition reduces blood aspartate transaminase (AST) level in the subject by at least 100 U/L after 15 days of treatment.
